Group items matching

in title, tags, annotations or url

The mission of the Crohn's & Colitis Foundation is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. In order to pursue this mission, the Crohn's & Colitis Foundation seeks to support and accelerate the discovery and development of research-based products with potential for positive impact for patients suffering from inflammatory bowel diseases (IBD). The Foundation hereby solicits proposals from companies and academic investigators seeking support for the discovery and development of such products. Proposals will be reviewed in order to determine whether programs are eligible for Foundation support through the Entrepreneurial Investing (EI) Initiative to fund the discovery and development of products with potential for benefit in the IBD field. Funded programs may be led by investigators at companies or academic institutions. The EI program is not a traditional research grant mechanism. Its objective is to identify and support organizations that will benefit from partnership with the Foundation in pursuit of product discovery and development. This document identifies program policies and terms, funding and resources available for fundees, eligibility, selection criteria and application procedures.

 Impact: Applications should articulate both the short- and long-term impact of the proposed research. Projects must address one or more of the FY18 SCIRP IIRA Focus Areas.  Military Relevance: Projects should be relevant to spinal cord-injured military Service members, Veterans, and/or their family members and caregivers. Collaboration with military and VA researchers and clinicians is encouraged.  Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the SCIRP and the proposed research project. IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as correlative studies associated with an existing clinical trial.

This notice solicits applications for the Health Center Program's Service Area Competition (SAC). The Health Center Program supports public and private nonprofit community-based and patient-directed organizations that provide primary health care services to the Nation's medically underserved populations. The purpose of the SAC NOFO is to ensure continued access to affordable, quality primary health care services for communities and vulnerable populations currently served by the Health Center Program. This NOFO details the SAC eligibility requirements, review criteria, and awarding factors for organizations seeking funding for operational support to provide primary health care services to an announced service area. For the purposes of this document, the term "health center" encompasses Health Center Program award recipients funded under the following subsections: Community Health Center (CHC - section 330(e)), Migrant Health Center (MHC - section 330(g)), Health Care for the Homeless (HCH - section 330(h)), and/or Public Housing Primary Care (PHPC - section 330(i)).

The Dermatology Foundation was established over fifty years ago to provide research funding that would help develop and retain talented new physician scientists and investigators, enabling advancements in patient care. Today, the foundation remains fully committed to furthering the specialty of dermatology by offering a variety of funding opportunities through its Research Awards Program. To advance this mission, the foundation is accepting applications for Career Development Awards. Through the program, grants of up $55,000 will be awarded in nine separate categories

The Alport Syndrome Foundation (ASF) is inviting applications for the Paul Silver Enrichment Award in memory of Paul Silver, an Alport syndrome patient. Silver was a film and music editor in Hollywood who passed away in 2004 at the age of 38. In 1985, he was a Communications major studying filmmaking at Pennsylvania State University and needed a camera to document his trip to Tuscany, Italy, where was he was planning to attend a summer study program. Silver applied for, and won, the Anthony Maimone Memorial Award and was able to make a documentary film for the university about his experiences in Italy and the benefits of the program. The purpose of the award is to "pay it forward" and help other young people affected by Alport syndrome achieve one of their goals. The award can be used to complete a project or pursue an activity that will enhance the applicant's life. The program is open to individuals between the ages of 16 and 22 affected by Alport syndrome.  The award selection committee has a total of $3,000 to award, at its discretion, to one or more applications. Applicants will be evaluated on the purpose and potential impact of the award, if the award will allow the applicant to achieve their stated goal, the quality of the essay, recommendation letters, and completeness of the submission. Applications will be accepted between September 1 and November 16, 2019, with winners to be notified in early January 2020.

The purpose of this FOA is to support a Multisite Clinical Center to implement the enrollment and multimodal longitudinal assessment of a large cohort of patients that EITHER experienced an acute musculoskeletal trauma OR an acute peri-operative pain event to identify a biosignature for resilience to and/or the transition from acute to chronic pain.

The American Kidney Fund is inviting applications for its Clinical Scientist in Nephrology (CSN) Program. For more than thirty years, the CSN fellowship program has funded researchers whose work is designed to improve the diagnosis and treatment of and outcomes for patients living with chronic kidney disease. CSN fellows conduct prevention and outcomes research while receiving advanced training in essential skills such as medical ethics, biostatistics, and epidemiology.

This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.

This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Pan-African Research Consortium (SPARCO) Hub in Tanzania to continue coordinating, as the Clinical Coordinating Center (CCC), activities of the renewed and expanded Consortium (SPARCO), including the 3 established sites in Ghana, Nigeria and Tanzania as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, the CCC, the Sickle Africa Data Coordinating Center (SADaCC, see RFA-HL-21-008), as well as established and new sites of the Consortium (RFA-HL-21-009) will constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims to develop a sustainable resource that will advance sickle cell disease related epidemiologic, translational, and clinical research studies. The SPARCO CCC application needs to propose a feasible and meritorious plan for expanding a sickle hemoglobinopathy registry database that can facilitate patient tracking and follow-up and serve as a backbone for future SCD research. In particular, this FOA seeks an application that proposes to identify database elements and plans for harmonization of SCD phenotype definitions and ontologies, and integration of Collaborative Consortium activities with those of the DCC (SADaCC), NHLBI, Steering Committee, Observational Study Monitoring Board (OSMB), and existing training programs. The application needs to describe approaches to the development of regionally appropriate standards of SCD care, as well as approaches to the organization of research and clinical skill development activities. The application also needs to include coordination of Consortium sites to allow for development, implementation, and conduct of SCD cohort studies, as well as implementation research of preventive/ therapeutic practices.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

Ohio is home to approximately 26,000 individuals living with paralysis as a result of a Spinal Cord Injury (SCI). According to the National SCI Statistical Center 66% of those individuals remain unemployed with each expected to manage lifetime healthcare costs of $1-3M. This represents a significant cost to the state and also imposes a severe burden on the quality of life for those living with this impairment. While there is research in pursuit of improved treatments to ameliorate the effects of paralysis, the field is significantly underfunded relative to similarly sized patient populations or disease with similar lifetime healthcare costs. While the scientific disciplines of neuroscience and biomedical engineering are making progress toward the development of new treatments, there is a lack of systematic and especially localized effort to guide these advances representative of the various stakeholders. The research funded through this process is specifically targeted to advance and accelerate the development of innovative treatments, product innovation and rehabilitative efforts that lead to the functional improvement of people living with spinal cord injuries. Research topics may include, but are not limited to, discovery science, pharmaceutical development, medical device design and implementation, and the development of novel rehabilitative approaches and techniques.

The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders.  Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs.

The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders. Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs. Another grant under (R21)

The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between minority variants and treatment outcomes and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between minority variants and treatment outcomes and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of imaging approaches to identify and characterize persistent HIV reservoirs in patients undergoing suppressive antiretroviral therapy (ART) and to quantify the nature and size of these reservoirs in response to therapeutic interventions.

This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports planning for a clinical trial and can include a small pilot clinical trial that a) incorporates emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) supports real-time clinical decision making, and c) facilitates effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.

The National Multiple Sclerosis Society mobilizes people and resources to find a cure for and address challenges faced by those affected by MS. To that end, the society is accepting applications for its Pilot Grant Program. The program funds high-risk pilot grants in support of novel ideas that may serve to advance its mission of stopping MS progression, restoring function, and improving quality of life for those with MS. The program supports fundamental as well as applied studies, both non-clinical or clinical in nature, including projects in patient management, care, and rehabilitation. One-year grants of up to $44,000 will be awarded to test innovative, cutting-edge ideas or untested methods, and to gather sufficient preliminary data that can be used to apply for longer-term funding. Researchers who have completed their postdoctoral training are invited to apply. Individuals who are currently postdoctoral fellows or the equivalent, or who are graduate/medical students are not eligible for support under this program. Pre-applications must be received no later than January 8, 2018.